Accessibility Menu
Allarity Therapeutics logo

Allarity Therapeutics(NASDAQ) ALLR

Current Price$1.24
Market Cap$18.62MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-100%
5 Year-100%
1 Year+17%
1 Month-18%
Allarity Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 1.172026-07-20
Allarity Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.54%USD 1.132026-07-13
1 month-18.18%USD 1.432026-06-18
3 month-15.22%USD 1.382026-04-21
Year to date+8.33%USD 1.082025-12-31
1 year+17.4%USD 1.002025-07-18
3 year-99.93%USD 1,782.002023-07-21
5 year-100%USD 1,226,400.002019-03-19
Since inception-100%USD 8,819,823.602021-12-21

Allarity Therapeutics Financials at a Glance

Market Cap

$18.62MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$345.00K

Net Income (TTM)

-$11.25M

EPS (TTM)

-$0.72

P/E Ratio

-1.62

Dividend

$0.00

Beta (Volatility)

1.08 (Average)

Price

$1.24

Volume

273

Open

$1.17

Previous Close

$1.17

Daily Range

$1.17 - $1.24

52-Week Range

$0.77 - $2.35

Estimated Earnings Date

Aug 21, 2026

ALLR News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Allarity Therapeutics

Allarity develops medicines for cancer patients who need new treatment options. Its technology helps doctors match patients to the right drug. This approach aims to improve outcomes for people with hard-to-treat cancers.

What’s in the Allarity Toolbox?

  • Stenoparib (PARP inhibitor): Drug in Phase 2 trials for ovarian cancer; helps block cancer cell repair.
  • IXEMPRA (microtubule inhibitor): Drug for advanced breast cancer; disrupts cancer cell division.
  • LiPlaCis (liposomal cisplatin): Reformulated chemotherapy for breast cancer; designed for targeted delivery.
  • 2X-111 (liposomal doxorubicin): Drug in trials for breast cancer and brain cancer; aims for better tumor targeting.
  • Drug Response Predictor (DRP): Diagnostic tool to identify which patients may benefit from specific drugs.
  • Laboratory Services: Provides DRP testing to other biotech companies; no revenue reported yet.

Growth Moves: Allarity’s Expansion Playbook

  • Launched on NASDAQ in December 2021 to access public capital markets.
  • Entered a global license deal for DRP algorithms with an EU biotech in July 2025.
  • Expanded clinical trials for Stenoparib in 2024 and 2025.
  • Terminated Dovitinib license with Novartis in January 2024, shifting focus to other drugs.
  • Raised $9.7 million through an equity offering in H1 2025; started a $5 million share buyback.

Why Allarity Catches the Eye

Allarity’s DRP technology helps match cancer patients to the most promising drugs. Its focus on precision medicine aims to make clinical trials more efficient. The company operates with a small team and relies on partnerships for global reach.

Five Things You Need to Know

  • No product revenue reported for Q2 2025 or prior periods.
  • Net loss was $2.3 million in Q2 2025, up 42% from Q2 2024.
  • Research and development spending rose 109% year-over-year in Q2 2025.
  • Cash and equivalents totaled $17.8 million as of June 30, 2025.
  • Share repurchase program authorized $5 million; $2.6 million spent by Q2 2025.

Bottom Line

Allarity is a small biotech focused on precision cancer drugs and diagnostics. Its future depends on clinical progress and continued access to funding.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

8

CEO

Thomas H. Jensen

Website

www.allarity.com

Headquarters

Tarpon Springs, FL 02139, US

ALLR Financials

Key Financial Metrics (TTM)

Gross Margin

107.54%

Operating Margin

-3552.75%

Net Income Margin

-3260.58%

Return on Equity

-109.94%

Return on Capital

-112.26%

Return on Assets

-32.21%

Earnings Yield

-61.73%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$18.62MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

15.91M

Volume

273

Avg. Volume

197.04K

Financials (TTM)

Gross Profit

$371.00K

Operating Income

-$12.26M

EBITDA

-$10.94M

Operating Cash Flow

-$16.63M

Capital Expenditure

-$64.00K

Free Cash Flow

-$16.70M

Cash & ST Invst.

$19.81M

Total Debt

$21.50M

Allarity Therapeutics Performance Analysis

Allarity Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 320,000N/A
Allarity Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31-92.2%
Allarity Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1,856,055.60-47.3%
20232023-12-31USD -6,153.26-99.7%
20242024-12-31USD -15.79-99.7%
20252025-12-31USD -0.78-95.1%
Allarity Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3040.0%
Q32025-09-30-26.7%
Q42025-12-31-10.5%
Q12026-03-3119.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$25.00K

N/A

Gross Profit

$51.00K

N/A

Gross Margin

2.04%

N/A

Market Cap

$18.62MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.66M

N/A

Employees

7

N/A

Net Income

-$2.75M

-0.7%

EBITDA

-$2.55M

+4.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$19.81M

-21.4%

Total Debt

$21.50M

+1477.1%

Accounts Receivable

$1.08M

-3.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$21.50M

+1477.1%

Return on Assets

-32.21%

N/A

Return on Invested Capital

-1.77%

N/A

Free Cash Flow

-$4.56M

-69.7%

Operating Cash Flow

-$4.49M

-67.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ENTOEntero Therapeutics, Inc.
$2.85-5.00%
CINGCingulate Inc.
$4.71+3.29%
CRISCuris, Inc.
$4.72+4.42%
BCTXBriaCell Therapeutics Corp.
$3.76+3.16%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$7.59+0.10%
NOKNokia
$10.62+0.05%
AALAmerican Airlines Group
$15.19+0.00%
HLHecla Mining
$15.15+0.06%

Questions About ALLR

What is the current price of Allarity Therapeutics?

Allarity Therapeutics is trading at $1.24 per share.

What is the 52-week range for Allarity Therapeutics?

Over the past 52 weeks, Allarity Therapeutics has traded between $0.77 and $2.35.

How much debt does Allarity Therapeutics have?

As of the most recent reporting period, Allarity Therapeutics reported total debt of $21.50M.

How much cash does Allarity Therapeutics have on hand?

Allarity Therapeutics reported $29.81M in cash and cash equivalents in its most recent financial results.

What is Allarity Therapeutics’s dividend yield?

Allarity Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services